Stock Ratings / Health Care / BDTX / dividends

VYGR (15) LENZ (44) ENGN (34) TVGN (40) ⌘ Pro Terminal →

Black Diamond Therapeutics Inc. (BDTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.86 +1.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.86

Black Diamond Therapeutics Inc. (BDTX) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $106.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BDTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $1.86 (+1.64% 1D, market cap $106.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BDTX ranks #189 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BDTX compare to VYGR and LENZ in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, VYGR (Voyager Therapeutics Inc.) holds a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M) and LENZ (LENZ Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BDTX?

▼

Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $0 in revenue, $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.86 (+0.11%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY BDTX SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 45.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.83-6% Next Q

Q2 (-2Q)

Grade C-$1.72+9.3% Next Q

Q3 (-1Q)

Grade C$1.88-1.1% Next Q

Current

Grade C-$1.86+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BDTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, BDTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.95) or 200D SMA ($2.19) invalidates the momentum regime and cuts Target Base ($1.87) toward Bear Floor ($1.46).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BDTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in BDTX & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on BDTX and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BDTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.81%📐 HORIZONTAL RANGE

2026-10-30O $1.85H $1.90L $1.76C $1.86VOL 518.7K

RES: $2.11SUP: $1.60SMA50: $1.95SMA200: $2.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDTX Butterfly Map → + Track BDTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-4.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BDTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BDTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDTX)

Health Care Rank #189 of 1016 ⚔️ VYGR vs BDTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDTX vs. VYGR, LENZ, ENGN, TVGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Black Diamond Therapeutics Inc. (BDTX) ranks #189 by composite RQD confidence (59/100, grade C-) and #651 by equity capitalization ($106.9M). Within this direct 5-issuer industry benchmark cohort, BDTX leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BDTX ACTIVE Black Diamond Therapeutics Inc.	C-	59/100	—	—	10.8%	+1.64%	$106.9M	Benchmark Subject
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-4.35%	$108.4M	/vygr-vs-bdtx →
LENZ LENZ Therapeutics Inc.	D	44/100	—	96.0%	-27.8%	+8.72%	$109.7M	/lenz-vs-bdtx →
ENGN enGene Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.16%	$102.5M	/engn-vs-bdtx →
TVGN Tevogen Inc.	D-	40/100	—	—	-35.0%	-3.04%	$95.2M	/tvgn-vs-bdtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701541

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Black Diamond Therapeutics Inc. (BDTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.37B, operating cash flow of $29.6M, and free cash flow of $29.6M (+147.5% YoY). On the balance sheet, BDTX closed FY2025 with $143.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$22.37B	$29.6M	$29.6M	$143.0M	—
FY2024 (FY)	2024-12-31	$0	-$69.68B	-$62.3M	-$62.3M	$122.6M	—
FY2023 (FY)	2023-12-31	$0	-$82.4M	-$66.7M	-$66.7M	—	—

3. BDTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BDTX compare to VYGR and LENZ in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BDTX?

Where is BDTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDTX last traded at $1.86 (+1.64% on volume of 551,021 shares), positioning the stock -4.62% below its 50-day simple moving average ($1.95) and -15.07% below its 200-day simple moving average ($2.19). Across its 52-week range of $1.60 to $4.94, BDTX sits at the 7.8% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.63 to $2.09).

BDTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BDTX pay a dividend and is it safe?

Black Diamond Therapeutics Inc. (BDTX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BDTX RQD Cockpit BDTX 12M Forecast BDTX Earnings & Move BDTX Dividends & DRIP BDTX Insiders & 13F BDTX Whale Options BDTX Profit Sankey BDTX News & Why